Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. - Wikidata - awgldk - TriplyDB

Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.

Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.

http://www.wikidata.org/entity/Q37235925

about

Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples Treatment of prediabetes Type 2 diabetes can be prevented with early pharmacological intervention Comparison of accuracy of diabetes risk score and components of the metabolic syndrome in assessing risk of incident type 2 diabetes in Inter99 cohort Thirty-one novel biomarkers as predictors for clinically incident diabetes Toward Big Data Analytics: Review of Predictive Models in Management of Diabetes and Its Complications Beta-cell age calculator, a translational yardstick to communicate diabetes risk with patients: tehran lipid and glucose study.A1C level and future risk of diabetes: a systematic review Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study.Association between protein signals and type 2 diabetes incidence Plasma heme oxygenase-1 concentration in relation to impaired glucose regulation in a non-diabetic Chinese population.Reduction of specific circulating lymphocyte populations with metabolic risk factors in patients at risk to develop type 2 diabetes Combined use of serum adiponectin and tumor necrosis factor-alpha receptor 2 levels was comparable to 2-hour post-load glucose in diabetes prediction.Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis.Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.Development of a multi-biomarker disease activity test for rheumatoid arthritis Biomarkers in fasting serum to estimate glucose tolerance, insulin sensitivity, and insulin secretion Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes.Risk assessment tools for identifying individuals at risk of developing type 2 diabetes.Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics Joint analysis of multiple biomarkers for identifying type 2 diabetes in middle-aged and older Chinese: a cross-sectional study Proteomic analysis of endoscopically (endoscopic pancreatic function test) collected gastroduodenal fluid using in-gel tryptic digestion followed by LC-MS/MS.Nutrigenomics and personalized diets: What will they mean for food?Emerging applications of metabolomic and genomic profiling in diabetic clinical medicine.Risk models and scores for type 2 diabetes: systematic review Biomarker models as surrogates for the disposition index in the Insulin Resistance Atherosclerosis Study Literature-based discovery of salivary biomarkers for type 2 diabetes mellitus.Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study.The multi-systemic nature of diabetes mellitus: Genotype or phenotype?The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers Microvesicles/exosomes as potential novel biomarkers of metabolic diseases Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.SLE-key(®) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(®).Antioxidation of Cerium Oxide Nanoparticles to Several Series of Oxidative Damage Related to Type II Diabetes Mellitus In Vitro Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99).Biomarkers for the prediction of type 2 diabetes and cardiovascular disease.Microfluidic strategies applied to biomarker discovery and validation for multivariate diagnostics.Obesity and type 2 diabetes: which patients are at risk?'Omics'-driven discoveries in prevention and treatment of type 2 diabetes.

P2860

Q21245257-76F3E1A5-7121-4736-8420-B804DFE5429C Q24289511-2E491182-4775-4B0A-8383-079118890CDF Q26783350-47A6CD49-45BC-49ED-902D-8971852538EC Q27694430-3D5924B0-BE16-46AA-900C-D2699348B062 Q28742005-FAFF56B7-F36F-433E-AAD4-D5903F37D775 Q28752614-2A2F91BF-79C9-489D-A2AF-9BB2D6C3C2BE Q31005299-B5020FAB-A43C-4394-86B9-771939483EAD Q33697591-BDCEA5FF-AD31-45C7-A529-7935B2A15965 Q33932887-BF15F3C8-2223-415A-A63D-803ADF2A8ECE Q33932928-4AB73356-99D9-4462-9DBE-5B52EE4130D8 Q34152210-EE494A6F-164D-4583-AAB4-F8AB46B12472 Q34199758-4C2B6475-E141-49BC-A2C5-C827633C2640 Q34257123-03BB14EE-D29C-4423-AE2E-2E80E7F13CB2 Q34277467-3086C881-8CD3-44A9-BEF9-292A6D2D81D0 Q34358741-FDA77DD9-F7F1-45D6-A136-841687ED9880 Q34608705-483B6F3E-B665-4B50-8153-981DFB15A804 Q34667793-CE5D308B-708C-4B4D-9383-3AA8C77AC293 Q34762360-77CC40F6-0DE8-4A0D-8F81-48755CAD1874 Q35078114-CC96E16B-5C50-4C70-B61F-A5E3D2505076 Q35095114-768B6328-26F0-44EB-8EA3-36F1D0D491DB Q35189544-73C4111B-3A67-4B85-AF21-3EF75AF1C100 Q35322384-9465B7EB-F118-4009-9224-78FC0A91A4B1 Q35535008-AF86E94B-62CC-467E-A9CF-40B9F2AC3B4E Q35551472-D70553B2-CD91-458B-AAFA-24C8947377B2 Q35563714-3DB0A7E6-52FF-41AE-94FA-A5BDF75FD25F Q35575823-975E8D6A-87D4-481D-93BF-CB287B4B6AA2 Q35581227-23737E7A-48F6-4AB0-933A-AC914E379236 Q35610345-666210BF-E9C9-448B-AF40-A5B9DDEE9302 Q35649826-223BDE5A-8E34-415F-B164-0F34E9263DC0 Q35919282-CD9A2E64-FF04-4B29-A5A9-B38CBCEC0CA5 Q36125465-EF11DD71-A349-4174-AD6D-5F43BF4CFE5A Q36175435-5CF1B26B-FD21-49D2-82B3-2895733FEDCA Q36402230-48A791DC-39A4-48E5-90E0-240C93D197FC Q36775795-FBD43E34-D595-455B-9921-B3CE8A20E15A Q37368317-2B12EE96-7A56-486A-ABCC-6880216D1AAA Q37404546-3A52B81F-4503-45B4-887A-924D531370AC Q37886659-F2773A92-4780-4D0E-A64A-7AF49CEDDCF9 Q37943855-55C431D3-ACC2-42A8-AE30-D4133DA9C858 Q37954693-E6959F36-A706-4EF1-999F-07417CBF8B7C Q38009358-1319A448-6D00-4589-B6D6-47760D806F13

P2860

Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.

http://www.wikidata.org/entity/Q37235925

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Development of a type 2 diabet ...... rkers from the Inter99 cohort.

@en

Development of a type 2 diabet ...... rkers from the Inter99 cohort.

@nl

type

label

Development of a type 2 diabet ...... rkers from the Inter99 cohort.

@en

Development of a type 2 diabet ...... rkers from the Inter99 cohort.

@nl

prefLabel

Development of a type 2 diabet ...... rkers from the Inter99 cohort.

@en

Development of a type 2 diabet ...... rkers from the Inter99 cohort.

@nl

P1433

Q37235925-801F176C-DD11-46A1-912E-8CFD8A717B50

P1476

Q37235925-AD3F05A9-3669-4722-B165-C5573BEB0F7A

P2093

Q37235925-09BFDC26-BF31-4AD7-A92E-7FCFCFF2FD6A

Q37235925-2EB7A5EB-9821-4FB8-A343-250B42DCB5B1

Q37235925-39EE56B0-3611-4A28-A740-CAC22DCEF04A

Q37235925-4225A30E-5242-4F47-B3AF-1A7969D43D1A

Q37235925-79CFC395-51FD-49BC-A693-01A4DD45EC0B

Q37235925-ACBEBE6A-6719-45C4-8FA7-5FB26E7D3697

Q37235925-AE270A17-EDBB-4852-9E8D-3DE7E051F2AD

Q37235925-CDFAC481-230A-466C-AB8F-F7D15A62C96D

Q37235925-ED716BC8-01F2-44E5-9EDA-86207164BAF3

Q37235925-F7B36D65-6EF6-40B0-9E88-D49694DB2EE8

P2860

Q37235925-09EE7B89-558E-44D5-BAD0-D7241F10A1D4

Q37235925-0DDDEB58-CA7E-4F3A-800D-F793961909DD

Q37235925-10370F23-F079-4DCA-AFBA-47073FC0CBB8

Q37235925-1C217CA0-C4A2-4867-8A25-1A7C20C28545

Q37235925-2027C158-0E81-4C84-8DF1-804A3B87C3B4

Q37235925-294FD3CF-CDDA-4133-80AE-507FD90D9A38

Q37235925-425D5325-1290-4EF4-A05C-DE8EF489847A

Q37235925-4B6A17F6-215C-495B-A7F4-77991FE81AFC

Q37235925-4E4EF026-3A49-49FC-9ED3-AB03AC96116B

Q37235925-5AAA1E6B-AA8A-40C5-8907-2DFA1B3E7C96

P304

Q37235925-C9E73FC4-E060-4A53-8A4A-0BDEC78D3701

P31

Q37235925-C1C43CEF-DD4E-4D0E-BF18-880A8AFE5DCC

P356

Q37235925-1360A3DB-EEFF-4597-91C6-0E302288535D

P407

Q37235925-E42D91F5-5FE6-42C0-8ED9-A3F6BD505FF9

P433

Q37235925-EB3DE83C-068F-435F-89AA-132658A04B24

P478

Q37235925-387A87AD-D7EE-49E2-9B4A-857C7906E57C

P50

Q37235925-A1E6B754-E2CF-4C82-AAE1-84C4E53D8E0E

Q37235925-C0A894EB-060F-4626-900E-92A66203E6E5

P577

Q37235925-BB31415D-3561-4C78-AAE3-BEDED50230D0

P5875

Q37235925-3B240E4A-50D5-4D78-90DA-BFCB81A5F12A

P698

Q37235925-6A8BB53D-484E-4920-8B96-56AB1E71DDC5

P921

Q37235925-20586879-E2AB-45AE-A650-210D2F7C2101

Q37235925-C7EFD5B4-EBBC-4978-82CB-82F0DEF7963B

P932

Q37235925-CB540D08-65E7-4614-B342-3F24DBFF1DF0

P356

P1433

P1476

Development of a type 2 diabet ...... rkers from the Inter99 cohort.

@en

P2093

Edward Moler

http://www.w3.org/2001/XMLSchema#string

Janice A Kolberg

http://www.w3.org/2001/XMLSchema#string

Knut Borch-Johnsen

http://www.w3.org/2001/XMLSchema#string

Michael P McKenna

http://www.w3.org/2001/XMLSchema#string

Michael W Rowe

http://www.w3.org/2001/XMLSchema#string

Mickey S Urdea

http://www.w3.org/2001/XMLSchema#string

Robert W Gerwien

http://www.w3.org/2001/XMLSchema#string

Sarah Hamren

http://www.w3.org/2001/XMLSchema#string

Torben Hansen

http://www.w3.org/2001/XMLSchema#string

Xiaomei M Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies

Progression from newly acquired impaired fasting glusose to type 2 diabetes

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Activated T lymphocytes in Type 2 diabetes: implications from in vitro studies.

Follow-up report on the diagnosis of diabetes mellitus.

Etiology of insulin resistance

State of diabetes care in the United States.

Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program

P304

1207-1212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC08-1935

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Oluf Borbye Pedersen

Torben Jørgensen

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26328492

http://www.w3.org/2001/XMLSchema#string

P698

19564473

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2699726

http://www.w3.org/2001/XMLSchema#string